• LAST PRICE
    11.8000
  • TODAY'S CHANGE (%)
    Trending Up0.2000 (1.7241%)
  • Bid / Lots
    9.2100/ 10
  • Ask / Lots
    15.7700/ 30
  • Open / Previous Close
    11.5000 / 11.6000
  • Day Range
    Low 11.5000
    High 12.0900
  • 52 Week Range
    Low 9.6800
    High 17.3100
  • Volume
    35,019
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 11.6
TimeVolumeARTV
09:53 ET10011.5
10:09 ET25012.07
10:29 ET10012.06
10:56 ET10012.0501
11:05 ET29512.08
11:07 ET127511.99
11:12 ET79911.93
11:14 ET22811.86
01:11 ET27011.75
02:05 ET20211.785
02:16 ET20011.7
02:59 ET19011.83
03:10 ET40011.93
03:12 ET70011.89
03:14 ET20011.72
03:51 ET40011.65
04:00 ET653811.8
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesARTV
Artiva Biotherapeutics Inc
286.6M
0.0x
---
United StatesACRS
Aclaris Therapeutics Inc
281.4M
-7.6x
---
United StatesMRSN
Mersana Therapeutics Inc
312.5M
-4.1x
---
United StatesFHTX
Foghorn Therapeutics Inc.
365.2M
-3.4x
---
United StatesTNGX
Tango Therapeutics Inc
363.6M
-2.9x
---
United StatesCRBU
Caribou Biosciences Inc
192.9M
-1.3x
---
As of 2024-12-07

Company Information

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. The Company's product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as LN, RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, SLE and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.

Contact Information

Headquarters
5505 Morehouse DriveSAN DIEGO, CA, United States 92121
Phone
858-267-4467
Fax
302-269-3855

Executives

Independent Chairman of the Board
Brian Daniels
President, Chief Executive Officer, Director
Fred Aslan
Chief Financial Officer, Executive Vice President - Corporate Development
Neha Krishnamohan
Chief Technical Operations Officer
Christopher Horan
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
Jennifer Bush

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$286.6M
Revenue (TTM)
---
Shares Outstanding
24.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
---
Book Value
$2.34
P/E Ratio
0.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.